NCT04712734View on ClinicalTrials.gov

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Schizophrenia
Interventions
DRUG

Iloperidone

oral tablet, long-acting injection

Trial Locations (3)

20877

Vanda Investigational Site, Gaithersburg

92845

Vanda Investigational Site, Garden Grove

08053

Vanda Investigational Site, Marlton

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY